Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies.

Abstract

Approaches for cervical cancer prevention are changing. Screening still remains the most effective method for cervical cancer prevention. Guidelines are moving to an older group of women to be screened less frequently with combinations of technologies that include biomarkers and cytology. HPV vaccination is an appropriate option for this older group of women as well, should the woman not wish to make her decision about vaccination until 21 years of age, the age of screening. Parents making decisions about HPV vaccination for their young adolescent daughters need to be fully informed that only continued screening prevents cervical cancer. HPV vaccination reduces the possibility of their daughter having an abnormal Pap test by 10% if the vaccines have not waned by the time the young adolescent becomes sexually active. HPV vaccine efficacy must last at least 15 years to contribute to the prevention of cervical cancers. At this time, protection against cervical intraepithelial neoplasia grade 2/3 (CIN 2/3) is 5 years for Gardasil and 8.4 years for Cervarix. The value of the current protection HPV vaccines offer will be viewed differently by different women. Physicians' ethical duties are to provide full explanation of the risks and benefits of adding HPV vaccination to the ongoing screening programs, and to support women in their personal choice for cervical cancer prevention.

• Authors: Diane M Harper, Karen B Williams
• Journal: Discovery medicine (Discov Med) Vol. 10 Issue 50 Pg. 7-17 (Jul 2010) ISSN: 1944-7930 [Electronic] United States
• PMID: 20670593 (Publication Type: Journal Article, Review)

Chemical References

• Cancer Vaccines
• Papillomavirus Vaccines

Topics

• Cancer Vaccines (immunology)
• Early Detection of Cancer
• Female
• Genital Neoplasms, Female (diagnosis, immunology, prevention & control)
• Humans
• Papillomavirus Vaccines (adverse effects, immunology)
• Vaccination (adverse effects)